Exclusive Summary

• • Hit the unmet needs: targeting patients with high LDL-C and high blood pressure.
• • In vivo PoC validated in NHP: at least comparable to combination efficacy and duration of Inclisiran and Zilebesiran.

Asset Materials

Contact Us for Full Materials